Zydus Lifesciences Limited, an innovation-led life-sciences company with an international presence, has closed its acquisition of Agenus Inc.’s biologics manufacturing facilities.

All acquired manufacturing assets and operations will be housed under a newly formed, dedicated U.S. based CDMO named Zylidac Bio LLC.

This acquisition provides Zydus immediate access to advanced biologics manufacturing capabilities and establishes a key presence in California, a leading global biotechnology hub. This strategic move also enables Zydus to leverage supply chain dynamics and a favorable geopolitical environment to expand its reach in the U.S. and globally. With this acquisition Zydus will now become a one stop solution provider across the entire development spectrum of biologics, right from pre-clinical to toxicology studies, clinical development and now manufacturing.

Zydus, Agenus Leadership React

Dr. Sharvil P. Patel, Managing Director of Zydus Lifesciences Limited, said, “With this deal, Zylidac Bio LLC will now provide biologicals manufacturing sites offering CDMO services to biopharmaceutical companies globally. This supports the evolving landscape of biological product manufacturing in the U.S., which prioritizes secure, domestic, and high-quality supply chains for advanced therapies. Zylidac Bio LLC offers a critical, compliant solution for global innovators and allows for a localized supply chain. It reinforces our ability to serve the international biopharmaceutical industry with reliability and innovation.”

Dr. Garo Armen, Chairman and CEO of Agenus Inc., added, “This collaboration unites Agenus’ pioneering immunotherapy pipeline and U.S.-based clinical development capabilities with Zydus’ global manufacturing, operational scale, and commercial infrastructure. The transaction allows Agenus to monetize manufacturing assets while securing dedicated, high-quality U.S. biologics capacity to support botensilimab and balstilimab.”

Other Pharma Industry Acquisitions

Check out Contract Pharma’s Pharmaceutical Industry Mergers & Acquisitions Roundup.